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Hance 1 
Abstract  
 Neonatal apnea is commonly treated by methylxanthines like caffeine or theophylline, 
but these drugs have the potential to create serious side effects. As an alternative, a new xanthine 
analog, 1-propylxanthine (1-PX), was recently synthesized at Eastern Illinois University. The 
respiratory effects of 1-PX were investigated in 4- to 7-day-old rats to determine if 1-PX could 
be a respiratory stimulant. Each rat was placed in a heated body plethysmograph, and its 
respiratory rate and volume were measured using a flow transducer, pneumotachograph, and 
Power Lab data acquisition system. After a 10-min control period, the rat was given a s.c. dose 
of 1-PX (10, 20, 40, or 80 mg/kg) or saline. Respiration was then recorded for one hour. Dose-
related increases were observed in respiratory rate and minute ventilation, while there were 
highly variable changes in tidal volume and a small increase in mean inspiratory flow. The 80 
mg/kg dose elicited a 32% increase in respiratory rate and an 8% increase in minute ventilation. 
A CO2-response study was also conducted on a separate group of rats in order to determine if 1-
PX increases the respiratory response to CO2. In the CO2-response study, each rat (4- to 7-days-
old) was placed in a heated body plethysmograph, and its respiratory rate and volume along with 
the inspired CO2 concentration were recorded by a flow transducer, pneumotachograph, Datex-
252 airway gas monitor, and PowerLab data acquisition system. Respiration was recorded for 10 
minutes while the rat was breathing room air (0% CO2). The CO2 concentration was then 
increased in 1% increments from 1-6%. After the initial CO2-response test, each rat received a 
s.c. injection of 20, 40, or 80 mg/kg 1-PX or saline. The CO2-response test was repeated at three 
15-min intervals after drug administration. Dose-related increases were observed in both minute 
ventilation and tidal volume, while there were highly variable changes in respiratory rate and  
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mean inspiratory flow. The 80 mg/kg 1-PX dose elicited a 127% increase in minute ventilation 
and an 84% increase in tidal volume. The results indicate that 1-PX is slightly less potent than 
theophylline and approximately equal in potency to 1-methylxanthine as a respiratory stimulant.  
 
Introduction 
 Pauses in breathing lasting from 6 to 10 seconds occur in all infants. These pauses are 
due to the immaturity of the respiratory system and are not necessarily harmful to the infant (1). 
If these pauses in breathing occur three or more times for more than three seconds with less than 
20 seconds in respiration between pauses, the condition is termed apnea (1). Apnea is not 
significant until the respiratory pauses last 20 seconds or longer or is coupled with bradycardia, 
cyanosis, or pallor (1). Apnea and the resultant combination of bradycardia and desaturation 
often require the use of pharmacological intervention that can cause serious side effects (2).  
 Methylxanthines are respiratory stimulants administered to neonates with apnea and have 
been shown to affect the child’s growth, neurological development, and behavior (3). In 
therapeutic ranges, theophylline, a methylxanthine, can cause side effects that include nausea, 
headache, diuresis, and occasionally cardiac arrhythmias and seizures (4). Theophylline  
(1,3-dimethylxanthine) has also caused tachycardia, vomiting, diarrhea, and abdominal 
distention at therapeutic concentrations (5).  Caffeine, another methylxanthine, has also been 
shown to cause tachycardia at therapeutic levels and to affect the central nervous system causing 
nervousness or anxiety, restlessness, tremors, insomnia, and hyperesthesia (6). 
 Neonatal apnea is thought to be caused by adenosine accumulation in the brain caused by 
the dephosphoylation of adenosine triphosphate (ATP) during hypoxia. Methylxanthines block  
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this hypoxia-induced apnea, and their therapeutic effects have been suggested to be due to the 
antagonistic action on adenosine receptors (7). Methylxanthines are the most common type of 
drug used to combat recurrent apnea in neonates because of the stimulatory effect that it has on 
the respiratory center. The most important therapeutic action of methylxanthines in children and 
adults is their ability to relax bronchial smooth muscle in order to increase air flow in diseases 
such as asthma (6). Methylxanthines also appear to cause an increased sensitivity of the 
medullary respiratory centers to the presence of CO2 which increases the respiratory minute 
volume in response to increased alveolar Pco2 (6).  
 The 1-position of alkylxanthines is thought to be essential for adenosine antagonism 
while the 3-position of xanthines is essential for increased bronchodilation. Both the 1-position 
and 3-position of alkylxanthines may increase toxic potency. The 7-position of xanthines 
decreases bronchodilation and toxic potency (8). Caffeine and theophylline, the two most used 
xanthines, both have methyl groups at the 1 and 3 positions while caffeine also has a methyl 
group at the 7-position (6). Since the 7-position causes decreased bronchodilation and the 3-
position has been shown to only enhance stimulation of respiration, the 1-position remains to be 
the cause of respiratory stimulation (9).  In this experiment, the respiratory effects of the new 
drug, 1-propylxanthine (1-PX), were observed in neonatal rats with the hypothesis that 1-PX 
increases the ventilation and increases the respiratory response to CO2 in neonatal rats. 
      
Materials and Methods 
 Setting up the equipment for the procedure began with connecting the Power Lab to the 
ETH-255 Bridge/ Bio Amplifier with a BNC cable plugged into the channel 1 output of the  
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amplifier to the front channel 1 input of the Power Lab unit. Channel 1 controls were set as 
follows: Gain= X1, Low Pass= 50 Hz, and High Pass= DC.  The power supply was then turned 
on to the water bath, pneumotachograph, Power Lab, amplifier, and computer. The Validyne 
model MC 1-3 pneumotachograph was attached to a Fleisch #0000 flow transducer and plugged 
into channel 1 of the amplifier. The chart program with approved settings was opened on the 
computer with channel 1 recording the flow, channel 2 recording the total volume, and channel 3 
recording the number of breaths. The instruments were calibrated to eliminate drift in the volume 
recording. The chart calibration included opening the Computed Input Column for channel 2 and 
turning the channel 1 offset knob to zero. The drift was rechecked before each animal treatment. 
The volume calibration was performed by filling a 20 ml syringe with exactly 20 ml of air and 
inserting the syringe on the left end of the flow transducer that is connected to the 
pneumotachograph. The reset button located on the chart calibration screen was clicked and the 
20 ml of air from the syringe was plunged into the flow transducer within 5 seconds. The reading 
on channel 2 should be 20 ml; if this was not the case, then the calibration was repeated. After 
the equipment was calibrated, the Computed Input screen was exited.   
 A newborn rat was randomly selected from a litter for a treatment. The rat was no less 
than 4 days old and no more than 7 days old. The rat’s mass, sex, age, and litter number were 
recorded in an Excel spreadsheet. An appropriate diaphragm with a hole in the center was 
selected according to the size of the rat and was placed over the lubricated end of the 
plethysmograph with a small rubber band. The rat’s head was forced through the hole in the 
diaphragm, and a plastic crosspiece was placed behind the rat to keep it from backing out. The 
end of the plethysmograph was plugged with a rubber stopper that contained a rubber tube that  
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would be attached to the flow transducer. Lubricant was applied around the neck of the rat to 
assure a tight seal. A small plastic cylinder was placed around the rat’s head to allow the rat to 
rest its chin, and this cylinder was held in place with tape. The plethysmograph was placed in the 
center of a jacketed water bath and the plastic tube from the plethysmograph was attached to the 
flow transducer of the pneumotachograph.  
 Recording was started and continued for ten minutes. After the initial ten minutes, two 
control measurements were taken by highlighting a ten second region of the graph in channel 1. 
The chart data was then copied and pasted into an Excel spreadsheet. The injection was prepared 
by determining the dose of 1-PX or saline (10 mg/kg with a concentration of 2 mg/ml, 20 mg/kg 
with a concentration of 4 mg/ml, 40 mg/kg with a concentration of 8 mg/ml, 80 mg/kg with a 
concentration of 16 mg/ml, or 0.9% NaCl) required by multiplying the rat’s mass by 5 
microliters/ gram. The 80 mg/kg 1-PX dose was derived from the 8 mg/ml solution by doubling 
the amount of the 8 mg/ml solution because there were solubility problems with higher 
concentrations of 1-PX. The 1-PX was synthesized by Dr. Howard Black and Aaron Lineberry of 
the Eastern Illinois University Chemistry Department. The 100 µl syringe was completely filled, 
the 26 gauge needle was attached, and the solution was pushed into the 26G needle until a drop 
of solution was ejected. The syringe was then filled completely to the determined amount, and 
the rat was injected under the scalp of the neck with a single subcutaneous dose of 1-PX (10, 20, 
40, or 80 mg/kg) or saline (0.9% NaCl) without removing the rat from the plethysmograph.  
 The plethysmograph was placed back into the jacketed water bath and attached to the 
right side of the flow transducer of the pneumotachograph. Recording was started immediately  
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after injection and continued for 60 minutes with 10 second recordings highlighted and saved to 
the Excel spreadsheet every 5 minutes. Eight rats were tested at each dose, with a total of 40 rats 
used in the study. 
 The same procedure as above was followed in the 1-PX CO2-response study with only a 
few differences. Again, 4- to 7-day-old rats were used in this experiment, but the treatments were 
reduced to saline, 20 mg/kg, 40 mg/kg, and 80 mg/kg of 1-PX. Setting up the equipment for the 
procedure began with connecting the Power Lab to the ETH-255 Bridge/ Bio Amplifier with a 
BNC cable plugged into the channel 1 output of the amplifier to the front channel 1 input of the 
Power Lab unit. Channel 1 controls were set as follows: Gain= X1, Low Pass= 50 Hz, and High 
Pass= DC.  The power supply was then turned on to the water bath, pneumotachograph, Power 
Lab, amplifier, Datex-252 airway gas monitor, and computer. The Datex-252 airway gas monitor 
was plugged into channel 1 of the amplifier while the Validyne model MC 1-3 
pneumotachograph was attached to a Fleisch #0000 flow transducer and plugged into channel 2 
of the amplifier. The chart program with approved settings was opened on the computer with 
channel 1 recording the flow, channel 2 recording the total volume, channel 3 recording the 
number of breaths, and channel 4 recording the CO2 concentration. The instruments were 
calibrated to eliminate drift in the volume recording. The chart calibration included opening the 
Computed Input Column for channel 2 and turning the channel 1 offset knob to zero. The drift 
was rechecked before each animal treatment. The volume calibration was performed by filling a 
20 ml syringe with exactly 20 ml of air and inserting the syringe on the left end of the flow 
transducer that is connected to the pneumotachograph. The reset button located on the chart 
calibration screen was clicked and the 20 ml of air from the syringe was plunged into the  
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flow transducer in about 5 seconds. The reading on channel 2 should be 20 ml; if this was not the 
case, then the calibration was repeated. After the equipment was calibrated, the Computed Input 
screen was exited.  
 A newborn rat (4-to 7-days-old) was randomly selected from a litter for a treatment. The 
rat’s mass, sex, age, and litter number were recorded in an Excel spreadsheet. An appropriate 
diaphragm with a hole in the center was selected according to the size of the rat and was placed 
over the lubricated end of the plethysmograph with a small rubber band. The rat’s head was 
forced through the hole in the diaphragm, and a plastic crosspiece was placed behind the rat to 
keep it from backing out. The end of the plethysmograph was plugged with a rubber stopper that 
contained both a rubber tube that would be attached to the pneumotachograph and a rubber tube 
that was attached to the gas mixer, Anthoson. Lubricant was applied around the neck of the rat in 
order to assure a tight seal. A small plastic cylinder was placed around the rat’s head to allow the 
rat to rest its chin, and this cylinder was held in place with tape. The plethysmograph was placed 
in the center of the jacketed water bath, and the plastic tube from the plethysmograph was 
attached to the flow transducer of the pneumotachograph. A rubber stopper plugged the other 
end of the jacketed water bath at the end closest to the rat’s head, and a thin tube was inserted 
through this rubber stopper into the jacketed water bath from the Datex-252 airway gas monitor. 
 Recording was started and continued for ten minutes while the rat was breathing room air 
(0% CO2). An air compressor generated this room air by sending room air to a gas mixer, 
Anthoson, that sent air into the jacketed water bath. The CO2 concentration was then increased in 
1% increments from 1 to 6% by mixing CO2 from a concentrated gas tank and room air from the 
air compressor with the gas mixer, Anthoson. The Datex-252 airway gas monitor detected the  
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carbon dioxide level in the jacketed water bath and sent the signal to the PowerLab data 
acquisition system, which converted this signal into quantitative data.  
 After the initial CO2-response test, the injection was prepared by determining the dose of 
1-PX (20 mg/kg with a concentration of 4 mg/ml, 40 mg/kg with a concentration of 8 mg/ml, or 
80 mg/kg with a concentration of 16 mg/ml) or 0.9% saline placebo required by multiplying the 
rat’s mass by 5 microliters/ gram. The 80 mg/kg 1-PX dose was derived from the 8 mg/ml 
solution by doubling the amount of the 8 mg/ml solution because there were solubility problems 
with higher concentrations of 1-PX. The 1-PX was synthesized by Dr. Howard Black and Aaron 
Lineberry of the Eastern Illinois University Chemistry Department. The 100 µl or 150 µl syringe 
was completely filled, the 26 gauge needle was attached, and the solution was pushed into the 
26G needle until a drop of solution was ejected. The syringe was then filled completely to the 
determined amount, and the rat was injected under the scalp with a single subcutaneous dose of 
1-PX or saline without removing the rat from the plethysmograph.  
 The plethysmograph was placed back into the jacketed water bath and attached to the 
right side of the flow transducer of the pneumotachograph. The CO2-response test was then 
repeated at 15, 30, and 45 minutes after drug administration. Minute ventilation (VE), respiratory 
rate (f), tidal volume (VT), and mean inspiratory flow (VT/TI) at the varying levels of inspired 
CO2 concentrations were collected by the PowerLab.  
 
Results 
 The rats given saline had an overall reduction in their mean percent change in f and VE 
with time, while the rats given lower doses of 1-PX had a decrease in mean percent change in  
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VE, but to a lesser extent than saline shown in Figure 1 and 2. There were dose-related increases 
in both mean percent change in f and VE compared to saline during the first 30 minutes after 
administration of 1-PX (Fig. 1, 2). The f was significantly higher than the saline controls in the 
20, 40, and 80 mg/kg 1-PX doses (p <0.01). The rats given the 80 mg/kg dose of 1-PX had the 
greatest increase in mean percent change in f and in VE as compared to the saline treatment. The 
40 mg/kg 1-PX dose elicited a greater response in the rats’ mean percent change in f and VE than 
the 20 mg/kg dose and the 10 mg/kg dose as compared to the saline dose. For example, at 30 
minutes the saline treatment elicited a 13% decrease in f and a 23% decrease in VE, the 10 mg/kg 
1-PX dose elicited a 7% decrease in f and a 13% decrease in VE, the 20 mg/kg 1-PX dose caused 
a 15% increase in f (p <0.05) and a 15% decrease in VE, and the 40 mg/kg 1-PX dose caused an 
11% increase in f (p <0.01) and a 10% decrease in VE, while the 80 mg/kg 1-PX dose elicited a 
26% increase in f (p <0.01) and an 8% increase in VE.  
 Figure 3 shows that the mean percent change in VT for the 10 mg/kg dose of 1-PX 
increased compared to the saline dose. Saline produced an 11% decrease in mean percent change 
in VT at 20 minutes, while the 10 mg/kg dose of 1-PX elicited a 4% decrease in mean percent 
change in VT at 20 minutes. The remaining doses of 20 mg/kg, 40 mg/kg, and 80 mg/kg 1-PX 
showed a decreased mean percent change in VT as compared to saline with the 80 mg/kg dose of 
1-PX causing the greatest decrease. The 20 mg/kg dose of 1-PX seems to decrease the mean 
percent change in VT more than the 40 mg/kg dose. No discernable pattern was seen in mean 
percent change of VT; therefore, there seems to be no correlation between dose and effects on 
VT. Mean percent change in VT/TI increased to a small extent by 1-PX shown in Figure 4.  
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 The VE, VT, and VT/TI increase in neonatal rat respiration both in the saline control 
treatment and in the 1-PX doses in response to CO2; however, the slopes of the 1-PX doses are 
steeper than the pre-injection control slopes. The f remains unchanged in neonatal rats in 
respiration response to CO2. Also, the pre- and post-injection CO2 response curves are very 
similar for the saline rats.  
 Within the CO2-response study, both mean percent change in VE and mean percent 
change in VT exhibited dose-related increases as seen in Figures 5-9. The effects of 1-PX on 
mean percent change of VE were clearly dose-related at 15 minutes post-injection as illustrated in 
Figure 5. The greatest increase in mean percent change in VE occurred 30 minutes post-injection; 
however, in this case, the 20 mg/kg 1-PX dose produced a slightly greater increase than the 40 
mg/kg 1-PX dose as depicted in Figures 6. At 15 minutes post-injection, 6% CO2 caused a 65% 
increase in mean percent change in VE for the saline dose (compared to a 54% increase pre-
injection), a 70% increase for the 20 mg/kg 1-PX dose, 82% increase for the 40 mg/kg 1-PX 
dose, and 100% increase for the 80 mg/kg dose, while the mean percent change in VE in response 
to 6% CO2 30 minutes post-injection was 76% for the saline dose (compared to a 54% increase 
pre-injection), a 99% increase for the 20 mg/kg 1-PX dose, a 90% increase for the 40 mg/kg 1-
PX dose, and a 127% increase for the 80 mg/kg 1-PX dose. Both Figures 6 and 7 depict dose-
related effects in mean percent change in VE at 30 and 45 minutes post-injection except that the 
20 mg/kg and 40 mg/kg 1-PX doses were reversed with the 20 mg/kg dose of 1-PX having a 
greater increase in mean percent change in VE than the 40 mg/kg dose of 1-PX.  
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 The greatest dose-related effects in mean percent change of VT occurred at 30 minutes 
post-injection while 15 minutes post-injection also showed dose-related effects but to a lesser 
extent than 30 minutes post-injection as illustrated in Figures 8 and 9. Mean percent change in  
VT 45 minutes post-injection showed no discernable pattern as seen in Figure 10. Mean percent 
change in f at 15, 30, and 45 minutes post-injection also displayed no discernable pattern; 
however, a flat response to CO2 was observed in the mean percent change in f, and this flat 
response was not altered by the drug treatment as depicted in Figures 11-13. Mean percent 
change in VT/TI at 30 and 45 minutes post-injection shows the 40 mg/kg 1-PX dose as the most 
effective dose while the other doses as well as the mean percent change in VT/TI at 15 minutes 
post-injection seems to illustrate no discernable pattern as shown in Figures 14-16.         
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Fig. 1. Time (min) vs mean percent change in respiratory rate of 8 neonatal rats injected with    
 doses of 10 mg/kg, 20 mg/kg, 40 mg/kg, and 80 mg/kg of 1-propylxanthine and saline. 
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Fig. 2. Time (min) vs mean percent change in minute ventilation of 8 neonatal rats injected with 
 doses of 10 mg/kg, 20 mg/kg, 40 mg/kg, and 80 mg/kg of 1-propylxanthine and saline. 
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Fig. 3. Time (min) vs mean percent change in tidal volume of 8 neonatal rats injected with 
 doses of 10 mg/kg, 20 mg/kg, 40 mg/kg, and 80 mg/kg of 1-propylxanthine and saline. 
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Fig. 4. Time (min) vs mean percent change in mean inspiratory flow of 8 neonatal rats injected 
 with doses of 10 mg/kg, 20 mg/kg, 40 mg/kg, and 80 mg/kg of 1-propylxanthine and 
 saline. 
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Fig. 5. Mean percent change from the 0% CO2 measurement in minute ventilation of 8 neonatal 
 rats 15 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 6. Mean percent change from the 0% CO2 measurement in minute ventilation of 8 neonatal 
 rats 30 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 7. Mean percent change from the 0% CO2 measurement in minute ventilation of 8 neonatal 
 rats 45 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 8. Mean percent change from the 0% CO2 measurement in tidal volume of 8 neonatal rats 15 
 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 9. Mean percent change from the 0% CO2 measurement in tidal volume of 8 neonatal rats 30 
 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 10. Mean percent change from the 0% CO2 measurement in tidal volume of 8 neonatal rats 
 45 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 11. Mean percent change from the 0% CO2 measurement in respiratory rate of 8 neonatal 
 rats 15 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 12. Mean percent change from the 0% CO2 measurement in respiratory rate of 8 neonatal 
 rats 30 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 13. Mean percent change from the 0% CO2 measurement in respiratory rate of 8 neonatal 
 rats 45 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 14. Mean percent change from the 0% CO2 measurement in mean inspiratory flow of 8 
 neonatal rats 15 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 15. Mean percent change from the 0% CO2 measurement in mean inspiratory flow of 8 
 neonatal rats 30 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Fig. 16. Mean percent change from the 0% CO2 measurement in mean inspiratory flow of 8 
 neonatal rats 45 minutes post-injection of 20 mg/kg, 40 mg/kg, and 80 mg/kg of  
 1-propylxanthine and saline. 
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Discussion 
 The results demonstrate that 1-PX stimulates respiration in neonatal rats and increases the 
ventilatory response to CO2. The response was dose-related, with the 80 mg/kg 1-PX dose 
eliciting the greatest increase in mean percent change in f and VE. For f, the 20, 40, and 80 mg/kg 
1-PX doses were all significantly different from saline. These results exhibit similarities to the 
respiratory effects produced by 1-methylxanthine (1-MX) (10). Both 1-PX and 1-MX increase f 
and VE without increasing VT. This study provides more supporting evidence that substitution in 
the 1-position is essential for stimulation of respiration by xanthine analogs. Comparison with 1-
MX suggests that the potency as a respiratory stimulant is not affected by the size of the alkyl 
group on the 1-position. A previous study indicated that 3-propylxanthine (enprofylline) did not 
stimulate respiration at doses up to 40 mg/kg (9), providing further supporting evidence that the  
1-position is essential for stimulation of respiration by xanthine analogs. The increase in mean 
percent change in VE produced by 80 mg/kg 1-PX is equivalent to the increase produced by 20 
mg/kg theophylline (1,3-dimethylxanthine) (10), results indicating that 1-PX is less potent than 
theophylline.  
 Mean percent change in VE was unusually high at 30 minutes post-injection of the 
highest dose of 1-PX. Five out of the 8 rats illustrated this jump in VE (a 4-day-old female, two 
4-day-old males, a 6-day-old female, and a 7-day-old female). Also, a 6-day-old male had 
increased VE, but not an extreme jump like the other 5 rats. Two samples (one from the 20 mg/kg 
data and one from the 40 mg/kg data) were thrown out and repeated due to computer problems 
and excessive rat movement. The effectiveness of 1-PX correlates with the dose and thus 
supports the hypothesis that 1-PX stimulates respiration in neonatal rats.  
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 The CO2-response results demonstrate that 1-PX stimulates respiration in neonatal rats 
under hypercapnic conditions. A flat f response to CO2 was observed and was unchanged by 1-
PX doses. Several previous studies have also observed this blunted f response to CO2 in the 
respiration of neonatal rats (11, 12). A similar flat f response to CO2 has been reported in 
premature human infants (13), justifying the use of newborn rats as a model for premature 
infants with breathing problems. The ventilatory response to CO2 was dose-related, with the 80 
mg/kg 1-PX dose eliciting the greatest response in VE. A similar increase in the VE response to 
CO2 has been observed in preterm infants receiving theophylline (5). The results from the CO2-
response curve also exhibit similarities between 1-PX and theophylline since both drugs 
increased VE primarily by increasing VT (14). While 1-PX does not appear to be superior to  
theophylline as a respiratory stimulant, the possibility that 1-PX has fewer side effects should be 
explored.       
 
 
 
 
 
 
 
 
 
 
Hance 22 
Works Cited 
1. Brouillette, R.T., Weese-Mayer, D.E., Hunt, and Carl E. Breathing control disorders in  infants 
 and children. Hosp. Prac. 1990; 25(8): 82-103.  
2. Martin, R.J. and Abu-Shaweesh, J.M. Control of breathing and neonatal apnea. Biol. Neonate. 
 2005; 87: 288-295. 
3. Millar, D. and Schmidt, B. Controversies surrounding xanthine therapy. Sem. Neonatol. 
 2004; 9: 239-244.  
4. Barnes, P.J. Drugs for asthma. Br. J. Pharmacol. 2006; 147: 297-303.  
5. Aranda, J.V., Chemtob, S., Laudignon, N., Sasyniuk, B.I. Pharmacologic effects of 
 theophylline in the newborn. J. Allergy Clin. Immunol. 1986; 78(4): 773-780.   
6. Rall, T.W. 1990. Drugs used in the treatment of asthma: The methylxanthines, 
 cromolyn sodium, and other agents. Goodman and Gillman. The Pharmacological Basis 
 of Therapeutics (8thed). Pergamon Press, New York. p. 618-630.  
7. Herlenius, E., Lagercrantz, H., and Yamamoto, Y. Adenosine modulates inspiratory neurons 
 and the respiratory pattern in the brainstem of neonatal rats. Pediatr. Res. 1997; 42(1):  
 46-53. 
8. Persson, C.G.A. Xanthines for asthma - present status. Trends Pharmacol. Sci. 1982; 312-313.     
9. McGilliard, K.L., Reynolds, S.M., and Gatto, C. Effects of xanthine analogs on respiratory 
 control in newborn rats. Modulations of Respiratory Pattern: Peripheral and Central 
 Mechanisms, 1990; p. 79.  
10. Gatto, C. Effects of Methylxanthines on Newborn Rat Respiration. Thesis. Eastern Illinois 
 University, 1989. 
Hance 23 
11. Martino, E.R. and McGilliard, K.L. Age related effects of aminophylline on the respiratory 
 response to CO2 in newborn rats. Abstracts, Board of Governors Universities Student 
 Research Conference, 1993; p. 22.  
12. Saeki, Y. and McGilliard, K.L. Effect of caffeine on the ventilatory response to CO2 in 
 newborn rats. Abstracts, 13th Annual Student Research Conference, 2002; p. 39.  
13. Rigatto, H. Brady, J.P., and Verduzco, R.T. Chemoreceptor reflexes in preterm infants: II. 
 The effect of gestational and postnatal age on the ventilatory response to inhaled carbon 
 dioxide. Pediatr. 1975; 55: 614-620. 
14. Davi, M.J., Sankaran, K., Simons, K.J., Simons, F.E.R., Seshia, M.M., Rigatto, H. 
 Physiological changes induced by theophylline in the treatment of apnea in preterm 
 infants. J. Pediatr. 1978; 92(1): 91-95.    
  
    
 
